

Mark Drakeford AC / AM
Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol
Minister for Health and Social Services



Llywodraeth Cymru
Welsh Government

Ein cyf/Our ref SF/MD/1653/14

Ann Jones AM
Chair
Children, Young People and Education Committee
National Assembly for Wales
Cardiff Bay
CF99 1NA

23 October 2014

Deu Ann,

Thank you for your letter of 15 October, requesting additional information to inform the Committee's inquiry into Child and Adolescent Mental Health Services (CAMHS). My comments in response to your questions are as follows and I look forward to receiving the Committee's final report in due course.

The level of CAMHS provision is not sufficient to meet the needs of young people in Wales who need a specialist, medical service.

I do not agree the level of CAMHS provision is insufficient to meet the needs of young people requiring a specialist service. By its very nature a specialist service concentrates and is highly skilled in working within a more restricted field. It was never the intention that specialist CAMHS should become the catch all for young people with emotional wellbeing and mental health problems. Alternatives would, and in many cases should, be more appropriate and beneficial for the individual allowing specialist CAMHS to concentrate on those with more complex and severe mental health problems. As my earlier evidence to Committee showed, specialist CAMHS have seen an increase of 103% in referrals between 2010 and 2014 and are seeing 70% more people within the 4 week target during the same period.

Those requiring specialist CAMHS, invariably do have their needs met, and where these are assessed to be urgent, or an emergency, then CAMHS responds accordingly, in a timely manner. There needs to be agreement among professionals, both in the NHS and partners elsewhere, as to how the needs of those young people who are inappropriately referred to specialist CAMHS can be catered for. There is evidence of good practice, in the work we are progressing through our service improvement plan, for example by engaging School Based Counselling; and through our multiagency Together for Mental Health Children, Young People and Families Delivery Assurance Group. However, more needs to be done to ensure CAMHS is organisationally and professionally geared to do what the highly skilled clinicians in the Service can do best. This is why I have asked Professor, Dame Sue Bailey, an internationally respected child psychiatrist and past president of the Royal College of

Bae Caerdydd • Cardiff Bay
Caerdydd • Cardiff
CF99 1NA

Wedi'i argraffu ar bapur wedi'i ailgylchu (100%)

English Enquiry Line 0845 010 3300
Llinell Ymholiadau Cymraeg 0845 010 4400
Correspondence: Mark.Drakeford@wales.gsi.gov.uk

Printed on 100% recycled paper

Psychiatrists, to lead the discussion on the future role of CAMHS. This will commence in earnest early in the new year.

That difficulties exist for those children and young people who do meet the criteria for CAMHS, including waiting times, clinic-based services and the use of prescription medication.

I have already acknowledged waiting lists are an issue which is being addressed through our service improvement plan. The problem has been exacerbated by too many inappropriate referrals into specialist CAMHS, which have to be seen and assessed, but which often do not reach the threshold for treatment. This is not acceptable, it takes up the limited time of specialist clinicians and, more importantly, is not in the interests of the young person. As an example in 2012, the NHS Delivery Unit (DU) undertook a contacts audit of CAMHS to gain an understanding of demand. This snapshot showed that of 2,400 contacts reviewed almost a quarter of new referrals were for anxiety (fear and phobia) (11.3%), low mood (6.7%) and relationship problems (6%). Many of these can be more appropriately dealt with in primary care, which is why we have invested in the development of Local Primary Mental Health Support Services, under the Mental Health (Wales) Measure; or by other partners, such as Schools Based Counselling, with support, rather than reliance on specialist CAMHS. This is in line with my priorities for prudent healthcare, enabling the most appropriate professional to work within their competency and ensuring the young person is not stigmatised from the outset as receiving specialist mental health services.

I agree clinic-based services are not always the most appropriate, although this will depend on the condition and individual circumstances. The NHS DU contacts audit showed 13% of all patient contact occurred in the patient's own home. Whether this should be higher will depend on our service reconfiguration work, led by Prof. Bailey. However, I also recognise the importance of CAMHS being accessible in the community and, for the first time, health boards have agreed the establishment of community Crisis Intervention and Treatment Teams. This is a key action in our service improvement plan and I am very pleased that health boards and the CAMHS/Eating Disorder Planning Network have been able to agree business cases and funding so quickly. Pending recruitment the teams should be fully operational across all-Wales, for the first time, from April 2015.

As for the use of prescription medicine, clinicians are bound to work within NICE guidelines and where these advocate prescription medicine as the optimum treatment, this is because there is a robust evidence base underpinning their effectiveness. Nevertheless, expanding the use of psychological therapies is a key commitment and one where I have invested £650,000 in the current year. I have provided further information in relation to the use of this funding in CAMHS in response to your question below.

The absence of services for those children and young people who do not meet the criteria for CAMHS means that there is a significant level of unmet need.

I agree with the Committee, the system as currently configured may not always work in the best interests of young people with emotional wellbeing and mental health needs. Here I include not just the NHS, but partner agencies also. You are aware I consequently asked that CAMHS work to address current problems with provision and also undertake a fundamental review of the shape of their services to ensure they are fit to meet the needs of children and young people for the future. Here the prudent principles I wish to see embedded in all services must be adopted at pace.

Services should carry out the minimum appropriate intervention, and for many young people inappropriate labelling and stigmatization with a mental illness at an early age will not help them. There are many services that, sometimes with the support of CAMHS, can work with

such children and young people effectively. This has to be part of the integrated approach that promotes cooperation rather than duplication. Similarly this brings in the principle of professionals across all disciplines and the “only do, what only you can do” principle. I am also keen to ensure, in order to promote equity, the principle that it is the individual’s clinical need which matters when it comes to deciding NHS treatment. This should mean those with the most acute clinical need are seen quickly, but those who have less acute needs must also be managed in a timely but proportionate manner.

That is why, to support CAMHS and its partners in this task, I am pleased that Prof. Sue Bailey has agreed to facilitate the challenging discussions needed to support service change. We have also placed Sian Richards, a former senior NHS Executive, to work alongside Carol Shillibeer (Chair of the CAMHS/Eating Disorder Planning Network) and the wider CAMHS network to support the transformational work. My intention is that this work should move CAMHS services significantly forward to make them fit for the future needs of young people, rather than services, which in some areas, developed from a model first designed as Child Guidance Clinics, many decades ago.

Whilst preliminary work has commenced, the major redesign work will commence on December the 5th when Professor Sue Bailey meets with officials and then key CAMHS stakeholders in the CAMHS Network meeting. Sue has already asked for, and received, a set of background briefing including work and evidence presented to the CYPE committee to inform her thinking. Sian Richards will also start inputting a significant amount time with WHSCC and the Network to support improvement in December.

The next major step will be when I launch a wider national conference and workshop session, planned for March to meet with a wider group of stakeholders from all sectors. Sue and Sian will work with the Network to shape the attendee list and discussions. The aim of the conference will be to begin to agree with stakeholders a consensus as to the shape of future services and meet the needs of those young people who have a need for specialist treatment, but also a plan as to how to respond to those who do not, and ensure effective provision is in place to meet their needs working with partner agencies. Change management and service redesign is a challenging task, but I am determined that we do agree a way forward at pace, the work aims to have an agreed plan with clear deliverables and dates for delivery by late 2015 .

I hope the committee will agree with me this root and branch review and work to modernise is an appropriate next step to be taken with pace and commitment following the Committee’s important work, which has highlighted some real concerns for us all.

An update on the analysis of prescribing trends, which was due to take place in October 2014.

I attach tables which show the prescribing trends for stimulant drugs used in treating attention deficit disorder for the period 2000 to mid 2014, using prescribing data held by NHS Wales Shared Services. The information is for total numbers of prescriptions dispensed. These do not equate to number of individuals treated who are likely to be receiving regular prescriptions. One table is provided for community prescribing the other for hospital prescribing. Prescribing information is not available at the individual patient level and therefore Shared Services are unable to undertake analysis by age. A proportion of these prescriptions will consequently be given to adults not under 18s. This group of drugs will also occasionally be used to treat narcolepsy a rare condition. However broadly speaking it is reasonable to assume the majority of such prescriptions will be given to young people receiving treatment for ADHD.

I should also add that as prescriptions for antidepressants and antipsychotics are also not available by age and the very large numbers of adults receiving prescription would entirely overwhelm the small numbers of young people receiving such treatment, I have not provided detailed information on any other drugs.

We are however scoping the potential and possible costs of utilising the Swansea University SAIL data for this purpose, as it has access to anonymised information held on GP systems including by age. I will consider whether to proceed if the benefits of 'mining' this information outweigh the costs associated with access.

An update on psychological therapies plans (which were due to be put in place by LHBs by August 2014).

Psychological therapy plans have now all been agreed and in respect of CAMHS the following will be funded. A summary of the plans is set out in Annex 1.

Best wishes,

Mark

Mark Drakeford AC / AM

Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol
Minister for Health and Social Services

Annex 1

Psychological Therapy Provision in CAMHS

Cwm Taf provider area (Cwm Taf, Abertawe Bro Morgannwg and Cardiff and Vale Health Boards)

Funding has been allocated to CAMHS, which will fund training to enable 10 staff to be trained to Improving Access to Psychological Therapies (IAPT) level C competence; 15 staff to undertake CBT for internalising disorders training; and 15 staff to undertake systemic training for depression and self-harm. All training will be undertaken between January and May 2015.

Aneurin Bevan Health Board

Dialectical Behaviour Therapy (DBT) - to repeat the highly successful and effective 10 day DBT training in house for up to two groups of staff (a total of 32) including a dedicated course for a significant section of our CAMHS and child and family workforce

Eye Movement Desensitisation and Reprocessing (EMDR) - to develop the specialist child skills of staff working with children and adolescents and invest in specialist additional training for three members of staff

Systemic Family Therapy - to buy in 5 skills refresher days for child and family services and run 2 further training days for staff in other parts of the service.

Attachment approaches - training psychologists and CAMHS nurses in Dyadic Developmental Psychotherapy.

Acceptance and Commitment Therapy (ACT) - two day introduction to ACT for staff across specialties and disciplines.

Betsi Cadwaladr Health Board

The Health Board will allocate circa 80 places to staff to undertake training in CBT. This will include Parabl (Tier 0); Local Mental Health Primary Support Service (Tier 1); CMHT (Tier 2); BCUHB volunteer counselling services, and specialist services, including inpatient, rehabilitation, OPMH and CAMHS

Powys Health Board

Have chosen to focus activity on older people in this funding round.

Hywel Dda Health Board

Dialectical Behaviour Therapy (DBT) – five day foundation training for four places.

Cognitive Behaviour Therapy Diploma – potential to train two staff in primary/secondary care to diploma level.

Acceptance Commitment Therapy – training 12 staff.

Assessment and Training Day – Psychology Solutions Partnership – training day for 35 staff.

Total Items				Year												
Chapter	Section	ChemicalName	Health Board	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	Jan-Jul '14		
Central Nervous System	Central Nervous System Stimulants	Atomoxetine Hydrochloride	Abertawe Bro Morgannwg University Health Board	80	505	599	659	739	765	926	1,120	1,194	1,192	766		
			Aneurin Bevan	16	358	427	411	428	491	578	638	565	578	332		
			Betsi Cadwaladr University Health Board	113	350	549	698	898	1,267	1,518	1,936	1,838	2,202	1,355		
			Cardiff And Vale University Health Board	224	803	899	968	847	832	928	1,348	1,390	1,465	1,075		
			Cwm Taf	265	807	729	717	846	837	912	940	1,003	942	576		
			Hywel Dda	96	441	614	623	568	558	607	581	502	626	445		
			Powys Teaching	27	127	167	186	182	186	158	140	181	157	71		
			Atomoxetine Hydrochloride Total	821	3,391	3,984	4,262	4,508	4,936	5,627	6,703	6,673	7,162	4,620		
		Dexamfetamine Sulphate	Abertawe Bro Morgannwg University Health Board	935	810	692	550	424	381	505	702	792	893	570		
			Aneurin Bevan	616	484	410	422	416	312	362	355	386	361	225		
			Betsi Cadwaladr University Health Board	501	504	486	601	707	650	607	648	668	686	382		
			Cardiff And Vale University Health Board	1,140	1,056	959	678	603	524	515	545	479	370	200		
			Cwm Taf	1,691	1,074	652	770	386	239	279	293	268	156	85		
			Hywel Dda	1,084	1,039	891	1,025	805	701	621	584	488	404	228		
			Powys Teaching	92	95	102	116	124	90	89	104	97	100	59		
			Dexamfetamine Sulphate Total	6,059	5,062	4,192	4,162	3,465	2,897	2,978	3,231	3,178	2,970	1,749		
		Lisdexamfetamine Dimesylate	Abertawe Bro Morgannwg University Health Board												4	10
			Aneurin Bevan												27	31
			Betsi Cadwaladr University Health Board												213	640
			Cardiff And Vale University Health Board												8	29
			Cwm Taf												3	14
			Hywel Dda												29	66
			Powys Teaching												2	3
			Lisdexamfetamine Dimesylate Total												286	793
Methylphenidate Hydrochloride	Abertawe Bro Morgannwg University Health Board	5,455	5,899	6,226	7,187	7,983	8,708	9,824	11,566	12,522	13,271	8,239				
	Aneurin Bevan	3,341	3,420	3,617	3,882	4,244	4,436	4,602	5,017	5,355	5,237	2,953				
	Betsi Cadwaladr University Health Board	5,955	7,303	9,374	11,891	13,481	14,883	16,195	18,298	19,745	21,273	12,736				
	Cardiff And Vale University Health Board	4,118	4,247	4,608	5,067	5,158	5,684	6,097	6,441	6,781	7,168	4,524				
	Cwm Taf	2,880	2,863	3,385	4,359	4,991	5,193	5,226	5,067	5,201	5,476	3,316				
	Hywel Dda	2,903	3,363	3,913	4,632	5,230	5,735	6,168	6,354	6,648	6,710	3,790				
	Powys Teaching	1,265	1,275	1,466	1,677	1,713	1,857	2,001	1,969	2,089	1,891	1,145				
	Methylphenidate Hydrochloride Total	25,917	28,370	32,589	38,695	42,800	46,496	50,113	54,712	58,341	61,026	36,703				
Grand Total					32,797	36,823	40,765	47,119	50,773	54,329	58,718	64,646	68,192	71,444	43,865	

1. Items with chemical name: methylphenidate, atomoxetine, dexamfetamine, lisdexamfetamine

Source: The data can be obtained from the **Prescription Cost Analysis (PCA)** data available at:

<http://wales.gov.uk/statistics-and-research/prescriptions-dispensed-community/?lang=en>

EXCEL files of summary prescription data and individual preparations are in the 'DETAILS' box on the right hand side of the page.

Note: Prescription statistics published here are based on information obtained from prescriptions sent to Prescribing Services, NHS Wales Shared Services Partnership for payment. Please see the statistical release and explanatory notes accompanying the PCA data and also the Quality Report written for information to aid understanding and to avoid any misinterpretation of the figures. All of these are accessible from the above link.

Sum of Items					Year														
Chapter	Section	ChemicalName	DrugName	Health Board	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	Jan-Jul '14	Grand Total			
Central Nervous System	Central Nervous System Stimulants	Atomoxetine Hydrochloride	Atomoxetine HCl_Cap 100mg	Abertawe Bro Morgannwg Uni										52	51	103			
				Aneurin Bevan													4	4	
				Betsi Cadwaladr Uni													16	42	58
				Cardiff And Vale Uni														12	12
				Cwm Taf													1	4	5
			Atomoxetine HCl_Cap 100mg Total														69	113	182
			Atomoxetine Hcl_Cap 10mg	Abertawe Bro Morgannwg Uni	2	24	25	78	119	108	162	195	202	164	102	164	102	1,181	
				Aneurin Bevan	3	50	56	40	32	59	98	120	104	106	65	733			
				Betsi Cadwaladr Uni	8	21	38	102	114	122	153	198	195	254	162	1,367			
				Cardiff And Vale Uni	36	95	85	125	108	100	140	283	230	228	177	1,607			
				Cwm Taf	34	51	79	77	93	36	75	91	105	90	46	777			
				Hywel Dda	10	62	169	154	125	135	168	159	111	135	109	1,337			
			Powys Teaching		9	46	60	58	49	35	18	12	13	5	305				
			Atomoxetine Hcl_Cap 10mg Total				93	312	498	636	649	609	831	1,064	959	990	666	7,307	
			Atomoxetine Hcl_Cap 18mg	Abertawe Bro Morgannwg Uni	3	38	58	61	55	54	70	71	84	66	46	606			
				Aneurin Bevan	3	40	44	10	17	27	34	28	26	30	14	273			
				Betsi Cadwaladr Uni	33	45	56	35	78	119	148	170	99	143	103	1,029			
				Cardiff And Vale Uni	26	86	88	83	66	86	86	87	74	89	52	823			
				Cwm Taf	33	54	30	35	19	10	13	44	44	36	42	360			
				Hywel Dda	10	50	78	54	79	90	49	48	66	50	52	626			
				Powys Teaching	2	8	17	9	7	15	20	7	9	21	1	116			
			Atomoxetine Hcl_Cap 18mg Total				110	321	371	287	321	401	420	455	402	435	310	3,833	
			Atomoxetine Hcl_Cap 25mg	Abertawe Bro Morgannwg Uni	4	82	159	112	113	175	177	196	151	179	144	1,492			
				Aneurin Bevan	3	101	121	125	131	138	111	104	109	99	46	1,088			
				Betsi Cadwaladr Uni	28	42	95	168	264	369	479	602	497	552	318	3,414			
				Cardiff And Vale Uni	35	116	142	175	171	177	150	213	185	196	167	1,727			
				Cwm Taf	48	132	121	157	138	113	97	89	106	118	63	1,182			
				Hywel Dda	8	60	67	96	88	87	108	87	86	116	78	881			
				Powys Teaching	2	19	9	42	34	46	35	29	36	26	10	288			
				Atomoxetine Hcl_Cap 25mg Total				128	552	714	875	939	1,105	1,157	1,320	1,170	1,286	826	10,072
Atomoxetine Hcl_Cap 40mg	Abertawe Bro Morgannwg Uni	6	161	155	224	275	184	135	233	310	302	155	2,140						
	Aneurin Bevan	2	98	113	126	128	149	141	178	151	168	103	1,357						
	Betsi Cadwaladr Uni	9	96	170	188	239	404	455	516	537	601	308	3,523						
	Cardiff And Vale Uni	41	256	285	212	228	234	225	333	297	306	238	2,655						
	Cwm Taf	40	165	213	199	198	160	193	160	189	231	117	1,865						
	Hywel Dda	35	121	138	155	160	162	174	172	143	193	93	1,546						
	Powys Teaching	8	30	39	29	20	33	39	51	66	57	31	403						
	Atomoxetine Hcl_Cap 40mg Total				141	927	1,113	1,133	1,248	1,326	1,362	1,643	1,693	1,858	1,045	13,489			
Atomoxetine Hcl_Cap 60mg	Abertawe Bro Morgannwg Uni	4	100	120	126	116	167	257	243	277	238	118	1,766						
	Aneurin Bevan		27	70	91	109	106	177	160	106	96	62	1,004						
	Betsi Cadwaladr Uni	8	72	122	169	164	176	179	261	361	385	252	2,149						
	Cardiff And Vale Uni	31	134	199	263	204	149	169	234	216	261	122	1,982						
	Cwm Taf	20	111	83	148	194	172	147	126	139	112	89	1,341						
	Hywel Dda		33	47	69	62	22	61	76	64	81	76	591						
	Powys Teaching	8	42	39	38	45	35	21	14	15	4	7	268						
Atomoxetine Hcl_Cap 60mg Total				71	519	680	904	894	827	1,011	1,114	1,178	1,177	726	9,101				
Atomoxetine HCl_Cap 80mg	Abertawe Bro Morgannwg Uni							5	26	100	93	94	123	441					
	Aneurin Bevan							1	3	16	32	29	30	111					
	Betsi Cadwaladr Uni								5	18	112	97	137	154	523				
	Cardiff And Vale Uni							1	5	17	56	168	152	141	540				
	Cwm Taf								5	23	62	71	72	42	275				
	Hywel Dda							1		5		8	10	7	31				
	Powys Teaching											5	9	14					
Atomoxetine HCl_Cap 80mg Total								2	21	92	346	469	499	506	1,935				
Atomoxetine Liq Spec 5mg/5ml				Cardiff And Vale Uni										1	1				
Atomoxetine Liq Spec 5mg/5ml Total														1	1				
Strattera_Cap 100mg	Abertawe Bro Morgannwg Uni													3	13	16			
	Cardiff And Vale Uni														7	7			
	Cwm Taf														1	1			
Strattera_Cap 100mg Total														4	20	24			
Strattera_Cap 10mg	Abertawe Bro Morgannwg Uni	16	6	3	5	3	9	18	11	7	2	80							
	Aneurin Bevan	3	16	2	1				2	12	9	45							
	Betsi Cadwaladr Uni	5	20	11	4	6	17	31	20	6	10	2	132						
	Cardiff And Vale Uni	9	11	6	13	11	16	29	39	38	25	20	217						
	Cwm Taf	19	73	15	8	38	45	81	68	38	13	11	409						
	Hywel Dda	10	18	35	23	11	18	8	12	6	4	145							

Central Nervous System	Central Nervous System Stimulants	Methylphenidate Hydrochloride											
		Concerta_XL Tab 27mg	Aneurin Bevan	8	53	123	153	237	315	438	302	1,629	
			Betsi Cadwaladr Uni	65	280	693	1,139	1,610	1,958	2,161	1,362	9,268	
			Cardiff And Vale Uni	78	190	291	357	612	740	826	485	3,579	
			Cwm Taf	137	380	558	635	625	719	971	619	4,644	
			Hywel Dda	12	65	147	280	269	341	393	205	1,712	
			Powys Teaching	12	52	38	48	83	103	110	69	515	
		Concerta_XL Tab 27mg Total		401	1,350	2,529	3,442	4,326	5,221	6,030	3,778	27,077	
		Equasym_XL_Cap 10mg	Abertawe Bro Morgannwg Uni	9	41	84	144	201	234	326	360	426	297
			Aneurin Bevan	2	5	38	88	101	94	124	176	189	88
			Betsi Cadwaladr Uni	66	226	437	523	487	596	656	657	758	433
			Cardiff And Vale Uni	52	80	128	156	241	288	354	411	488	277
			Cwm Taf	5	11	48	168	207	150	152	171	156	56
			Hywel Dda	12	80	144	276	324	419	430	448	437	231
			Powys Teaching	2	4	12	23	41	56	64	61	102	59
		Equasym_XL_Cap 10mg Total		148	447	891	1,378	1,602	1,837	2,106	2,284	2,556	1,441
		Equasym_XL_Cap 20mg	Abertawe Bro Morgannwg Uni	37	140	231	371	385	442	576	701	754	456
			Aneurin Bevan	2	43	92	147	224	285	335	367	594	312
			Betsi Cadwaladr Uni	166	461	730	995	900	1,015	1,318	1,358	1,395	726
			Cardiff And Vale Uni	121	256	336	405	580	808	830	902	1,011	637
			Cwm Taf	10	33	100	383	580	640	566	589	431	264
			Hywel Dda	20	109	164	292	538	593	683	727	774	472
			Powys Teaching		36	43	45	55	99	95	108	138	90
		Equasym_XL_Cap 20mg Total		356	1,078	1,696	2,638	3,262	3,882	4,403	4,752	5,097	2,957
		Equasym_XL_Cap 30mg	Abertawe Bro Morgannwg Uni	13	101	232	294	455	570	738	893	1,033	634
			Aneurin Bevan	10	19	48	158	217	271	303	413	416	264
			Betsi Cadwaladr Uni	58	267	553	875	1,129	1,341	1,370	1,399	1,594	954
			Cardiff And Vale Uni	45	118	197	246	387	423	683	882	905	598
			Cwm Taf	9	26	65	212	482	548	591	532	442	172
			Hywel Dda	1	32	129	150	243	423	457	537	663	424
			Powys Teaching	1	18	36	90	74	78	97	155	224	144
		Equasym_XL_Cap 30mg Total		137	581	1,260	2,025	2,987	3,654	4,239	4,811	5,277	3,190
		Equasym_Tab 10mg	Abertawe Bro Morgannwg Uni	52	30	46	73	50	36	50	8		345
			Aneurin Bevan	62	77	91	81	55	38	47	11		462
			Betsi Cadwaladr Uni	81	93	78	98	101	104	81	26		665
			Cardiff And Vale Uni	48	75	107	122	129	221	257	30	1	990
			Cwm Taf	9	24	38	24	19	55	54	2	2	227
			Hywel Dda	96	61	76	70	89	128	166	22		708
			Powys Teaching	72	70	86	35	44	58	66	10		441
		Equasym_Tab 10mg Total		420	430	522	503	487	640	721	109	2	1
		Equasym_Tab 20mg	Abertawe Bro Morgannwg Uni	1	1	1	8	15	27	23	1		77
			Aneurin Bevan	4	6	10	20	13	26	26	15		120
			Betsi Cadwaladr Uni	6	16	29	40	25	27	40		1	184
			Cardiff And Vale Uni	9	17	7	16	25	9	21	6		110
			Cwm Taf	2	1		6	5	12	23	8		57
			Hywel Dda	1	1	7	4	1	5	11	4		34
			Powys Teaching	29	15	15	20	1	5	11	1		97
		Equasym_Tab 20mg Total		52	57	69	114	85	111	155	35	1	679
		Equasym_Tab 5mg	Abertawe Bro Morgannwg Uni	80	68	68	53	55	99	90	8		521
			Aneurin Bevan	129	115	137	82	44	29	55	8		599
			Betsi Cadwaladr Uni	114	97	73	60	41	60	55	12	1	513
			Cardiff And Vale Uni	119	86	138	138	101	196	224	30	1	1,033
			Cwm Taf	12	20	22	26	15	15	32	3	1	146
			Hywel Dda	147	144	162	125	152	98	100	23	1	952
			Powys Teaching	34	48	58	34	29	30	20	3		256
		Equasym_Tab 5mg Total		635	578	658	518	437	527	576	87	3	1
		Medikinet_XL_Cap 10mg	Abertawe Bro Morgannwg Uni				1	25	41	56	133	196	125
			Aneurin Bevan					7	14	10	6	8	19
			Betsi Cadwaladr Uni			1	27	129	223	343	437	640	467
			Cardiff And Vale Uni					18	14	23	78	82	62
			Cwm Taf					5	16	14	4	10	47
			Hywel Dda			1	2	8	5	38	59	102	44
			Powys Teaching				23	117	141	84	85	69	46
		Medikinet_XL_Cap 10mg Total				2	65	327	448	554	810	1,155	783
		Medikinet_XL_Cap 20mg	Abertawe Bro Morgannwg Uni				1	34	143	152	200	323	202
			Aneurin Bevan				4	7	3	21	6	26	45
			Betsi Cadwaladr Uni				29	168	249	344	467	649	419
			Cardiff And Vale Uni				5	11	10	8	58	70	67
			Cwm Taf					17	47	16	16	56	35

Central Nervous System

Central Nervous System Stimulants

Methylphenidate Hydrochloride

Medikinet XL_Cap 20mg	Hywel Dda	2	6	33	34	64	103	108	55	405		
	Powys Teaching	1	47	92	113	101	117	63	30	564		
Medikinet XL_Cap 20mg Total		3	92	362	599	706	967	1,295	853	4,877		
Medikinet XL_Cap 30mg	Abertawe Bro Morgannwg Uni	2	14	46	170	149	212	341	223	1,157		
	Aneurin Bevan		8	8	12	26	12	10	13	89		
	Betsi Cadwaladr Uni		25	127	263	412	524	629	373	2,353		
	Cardiff And Vale Uni	1	14	5	16	25	39	30	35	165		
	Cwm Taf		3	23	37	48	76	93	99	379		
	Hywel Dda		10	32	42	53	92	103	41	373		
	Powys Teaching		33	78	81	97	141	91	36	557		
Medikinet XL_Cap 30mg Total		3	107	319	621	810	1,096	1,297	820	5,073		
Medikinet XL_Cap 40mg	Abertawe Bro Morgannwg Uni	1	9	40	99	176	255	352	212	1,144		
	Aneurin Bevan		2	5	3	5	19	30	6	70		
	Betsi Cadwaladr Uni	8	33	132	308	473	625	669	390	2,638		
	Cardiff And Vale Uni				4	1	8	15	9	37		
	Cwm Taf	1	14	20	36	42	70	85	53	321		
	Hywel Dda	2	22	22	18	26	61	82	38	271		
	Powys Teaching		12	20	36	35	28	11	13	155		
Medikinet XL_Cap 40mg Total		12	92	239	504	758	1,066	1,244	721	4,636		
Medikinet XL_Cap 50mg	Abertawe Bro Morgannwg Uni								1	1		
	Aneurin Bevan								1	1		
	Betsi Cadwaladr Uni								2	2		
	Cwm Taf								1	1		
Medikinet XL_Cap 50mg Total									5	5		
Medikinet XL_Cap 5mg	Abertawe Bro Morgannwg Uni					2	24	43	25	94		
	Aneurin Bevan						2	4	1	7		
	Betsi Cadwaladr Uni					13	116	229	157	515		
	Cardiff And Vale Uni					5	27	38	33	103		
	Cwm Taf					1	7	6	18	32		
	Hywel Dda					4	19	13	17	53		
	Powys Teaching					1	8	17	17	43		
Medikinet XL_Cap 5mg Total						26	203	350	268	847		
Medikinet XL_Cap 60mg	Abertawe Bro Morgannwg Uni								1	1		
Medikinet XL_Cap 60mg Total									1	1		
Medikinet_Tab 10mg	Abertawe Bro Morgannwg Uni			2	1	11	29	32	17	92		
	Aneurin Bevan					5	16	16	18	55		
	Betsi Cadwaladr Uni			3	24	56	140	137	80	440		
	Cardiff And Vale Uni				1	4	22	14	14	55		
	Cwm Taf					4	8	24	8	44		
	Hywel Dda		3	6		24	34	21	17	105		
	Powys Teaching	1	4	9	26	66	79	60	24	269		
Medikinet_Tab 10mg Total		1	7	20	52	170	328	304	178	1,060		
Medikinet_Tab 20mg	Abertawe Bro Morgannwg Uni				1	2	7	10	2	22		
	Aneurin Bevan					2	9	2	10	23		
	Betsi Cadwaladr Uni			1	1	9	39	96	48	194		
	Cardiff And Vale Uni							2	2	4		
	Cwm Taf		1	2				8	4	15		
	Hywel Dda					1	7	11	4	23		
	Powys Teaching		1	3	4	17	26	6	57	105		
Medikinet_Tab 20mg Total			1	5	8	31	88	135	70	338		
Medikinet_Tab 5mg	Abertawe Bro Morgannwg Uni					20	29	41	30	120		
	Aneurin Bevan			1	1	15	25	27	19	88		
	Betsi Cadwaladr Uni			2	4	69	108	102	48	333		
	Cardiff And Vale Uni				2	16	40	30	25	113		
	Cwm Taf				8	12	12	29	16	77		
	Hywel Dda			4	10	47	56	56	30	203		
	Powys Teaching	1	16	28	23	35	46	31	16	196		
Medikinet_Tab 5mg Total			1	16	35	48	214	316	184	1,130		
Methylphenidate HCl_Cap 10mg M/R	Abertawe Bro Morgannwg Uni	6	38	60	65	60	70	91	100	86	45	
	Aneurin Bevan	5	48	61	46	47	30	37	42	13	16	
	Betsi Cadwaladr Uni	16	90	127	116	114	80	83	32	44	21	
	Cardiff And Vale Uni	11	47	46	19	17	18	54	38	47	16	
	Cwm Taf	5	14	15	24	27	48	54	37	17	10	
	Hywel Dda	6	60	142	138	135	77	75	40	18	16	
	Powys Teaching	2	3	8	37	64	57	53	34	27	12	
Methylphenidate HCl_Cap 10mg M/R Total		51	300	459	445	464	380	447	323	252	136	
Methylphenidate Hcl_Cap 20mg M/r	Abertawe Bro Morgannwg Uni	1	10	51	53	67	83	115	114	122	52	44
	Aneurin Bevan	3	26	57	96	114	66	75	71	35	14	14

Analysis of community pharmacy prescriptions by LHB per 100,000 population: January - July 2014

	Abertawe Bro Morgannw g	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys	Wales
Atomoxetine Hydrochloride	766	332	1355	1075	576	445	71	4620
Dexamfetamine Sulphate	570	225	382	200	85	228	59	1749
Lisdexamohetamine Dimesylate	10	31	640	29	14	66	3	793
Methylphenidate Hydrochloride	8239	2953	12736	4524	3316	3790	1145	36703
Total	9585	3541	15113	5828	3991	4529	1278	43865
Population*	520710	579101	691986	478869	295135	383906	132705	3082412
Prescriptions per 100,000 pop	1841	611	2184	1217	1352	1180	963	1423

* Population figure used is mid year 2013 estimate

Number	Year												
Drug Name	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	
ATOMOXETINE			106	466	304	552	475	647	569	564	711	789	
DEXAMFETAMINE SULPHATE	250	360	335	336	312	321	323	275	273	227	132	596	
LISDEXAMPHETAMINE DIMESYLATE												69	
METHYLPHENIDATE	1,443	1,645	2,096	1,953	2,579	3,035	3,140	3,218	3,406	3,640	3,697	4,598	
Grand Total	1,693	2,005	2,537	2,755	3,195	3,908	3,938	4,140	4,248	4,431	4,540	6,052	

Value	Year												
Drug Name	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	
ATOMOXETINE			£4,665.14	£17,090.10	£12,196.95	£21,269.19	£25,027.59	£32,074.11	£30,889.97	£32,076.62	£40,128.82	£41,945.27	
DEXAMFETAMINE SULPHATE	£1,079.00	£1,402.19	£1,351.46	£1,870.76	£1,646.27	£1,759.86	£1,972.18	£2,137.47	£5,328.70	£12,814.88	£11,588.64	£20,527.51	
LISDEXAMPHETAMINE DIMESYLATE												£2,789.09	
METHYLPHENIDATE	£16,757.76	£22,396.79	£29,690.12	£28,690.10	£48,922.82	£62,170.80	£68,853.10	£76,184.56	£88,342.97	£98,131.78	£89,584.25	£105,411.70	

Hospital Pharmacy Data - The figures supplied represent the number of issues from Hospital Pharmacies.

An issue can be either items dispensed to a patient or can be a bulk issue to a ward or clinic.

The current hospital pharmacy system does not allow for any further breakdown of hospital prescribing data

Number	Trust name	Drug Name	Year												
			2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	
ABMU		ATOMOXETINE				74	130	78	231	174	270	238	127	158	179
		DEXAMFETAMINE SULPHATE	55	39	57	63	64	48	69	88	124	143	101	138	
		LISDEXAMPHETAMINE DIMESYLATE													2
		METHYLPHENIDATE	246	291	317	270	275	445	705	1,026	935	941	699	1,146	
ABMU Total			301	330	448	463	417	724	948	1,384	1,297	1,211	958	1,465	
Aneurin Bevan		ATOMOXETINE						7	24	11	10	8	1	5	1
		DEXAMFETAMINE SULPHATE	19	11	12	6	9	30	36	21	4	3	4	28	
		METHYLPHENIDATE	134	197	146	155	185	110	81	81	59	30	8	8	
Aneurin Bevan Total			153	208	158	161	201	164	128	112	71	34	17	37	
BCU		ATOMOXETINE								4		2		38	4
		DEXAMFETAMINE SULPHATE	28	14	37	6	25	17	36	24	22	20	3	308	
		METHYLPHENIDATE	129	49	38	73	52	52	84	66	100	111	222	182	
BCU Total			157	63	75	79	77	69	124	90	124	131	263	494	
Cardiff & Vale		ATOMOXETINE				169	88	115	111	116	93	169	132	150	
		DEXAMFETAMINE SULPHATE	98	189	123	144	113	137	54	27	15	4	1	6	
		METHYLPHENIDATE	665	793	1,139	993	1,165	1,240	1,169	1,137	1,272	1,279	1,279	1,456	
Cardiff & Vale Total			763	982	1,262	1,306	1,366	1,492	1,334	1,280	1,380	1,452	1,412	1,612	
Cwm Taf		ATOMOXETINE			23	83	23	48	36	137	98	101	125	213	
		DEXAMFETAMINE SULPHATE	38	47	40	39	16	19	54	49	52	16	18	37	
		METHYLPHENIDATE	135	161	256	126	271	318	332	380	458	555	862	1,104	
Cwm Taf Total			173	208	319	248	310	385	422	566	608	672	1,005	1,354	
Hywel Dda		ATOMOXETINE			9	84	108	134	139	114	130	166	253	242	
		DEXAMFETAMINE SULPHATE	12	57	58	74	71	66	70	57	56	40	5	76	
		LISDEXAMPHETAMINE DIMESYLATE												67	
		METHYLPHENIDATE	133	154	199	335	631	869	769	527	582	716	615	702	
Hywel Dda Total			145	211	266	493	810	1,069	978	698	768	922	873	1,087	
Velindre		DEXAMFETAMINE SULPHATE		3	8	4	14	4	4	9		1		3	
		METHYLPHENIDATE	1		1	1		1		1		8	12		
Velindre Total			1	3	9	5	14	5	4	10		9	12	3	
Grand Total			1,693	2,005	2,537	2,755	3,195	3,908	3,938	4,140	4,248	4,431	4,540	6,052	

Value		Year											
Trust name	Drug Name	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
ABMU	ATOMOXETINE			£3,320.45	£5,340.99	£3,719.17	£8,222.89	£9,312.48	£14,802.68	£13,925.32	£11,123.14	£11,828.50	£11,476.92
	DEXAMFETAMINE SULPHATE	£172.85	£152.61	£170.91	£280.93	£267.32	£246.48	£448.56	£845.83	£2,769.03	£9,550.31	£9,484.31	£11,797.60
	LISDEXAMPHETAMINE DIMESYLATE												£152.21
	METHYLPHENIDATE	£4,328.61	£5,105.63	£5,251.06	£4,545.00	£5,899.01	£10,652.64	£21,777.09	£33,588.99	£37,320.13	£35,587.24	£23,925.84	£33,916.41
ABMU Total		£4,501.46	£5,258.23	£8,742.42	£10,166.92	£9,885.50	£19,122.02	£31,538.14	£49,237.50	£54,014.48	£56,260.69	£45,238.65	£57,343.13
Aneurin Bevan	ATOMOXETINE					£114.31	£315.93	£133.75	£171.45	£966.11	£15.38	£138.21	£74.95
	DEXAMFETAMINE SULPHATE	£62.64	£9.04	£12.68	£5.35	£8.99	£67.95	£180.19	£74.43	£4.20	£6.33	-£3.43	£131.05
	METHYLPHENIDATE	£1,023.58	£1,563.35	£1,025.04	£1,119.89	£1,575.36	£1,034.94	£506.93	£685.77	£666.32	£575.67	£204.77	£116.00
Aneurin Bevan Total		£1,086.22	£1,572.39	£1,037.72	£1,125.24	£1,698.66	£1,418.82	£820.87	£931.65	£1,636.63	£597.38	£339.55	£322.00
BCU	ATOMOXETINE							£125.97		£136.37		£524.75	£187.39
	DEXAMFETAMINE SULPHATE	£30.71	£14.31	£20.15	£1.20	£33.89	£24.99	£59.17	£32.20	£125.58	£375.69	£17.53	£5,098.53
	METHYLPHENIDATE	£2,502.47	£154.09	£222.14	£821.45	£348.38	£239.16	£797.93	£627.34	£2,634.88	£2,381.64	£4,348.49	£2,632.94
BCU Total		£2,533.18	£168.40	£242.29	£822.65	£382.27	£264.15	£983.07	£659.54	£2,896.83	£2,757.33	£4,890.77	£7,918.86
Cardiff & Vale	ATOMOXETINE				£5,930.41	£3,622.10	£4,700.11	£4,765.52	£5,296.83	£4,407.10	£7,890.03	£8,049.03	£8,244.64
	DEXAMFETAMINE SULPHATE	£518.53	£510.18	£356.56	£539.17	£344.63	£359.47	£131.09	£56.33	£96.85	-£43.34	£0.49	£94.50
	METHYLPHENIDATE	£5,836.26	£8,873.76	£14,828.26	£14,424.82	£22,912.70	£25,107.50	£23,095.07	£20,134.59	£21,378.56	£25,366.39	£25,698.88	£28,634.04
Cardiff & Vale Total		£6,354.79	£9,383.94	£15,184.82	£20,894.40	£26,879.43	£30,167.08	£27,991.68	£25,487.75	£25,882.51	£33,213.08	£33,748.40	£36,973.18
Cwm Taf	ATOMOXETINE			£586.59	£2,199.62	£1,471.64	£1,361.06	£926.82	£4,362.95	£4,275.33	£3,968.60	£5,849.43	£8,839.91
	DEXAMFETAMINE SULPHATE	£254.76	£271.32	£313.75	£370.08	£267.10	£373.24	£496.87	£474.37	£1,090.42	£1,290.75	£2,041.02	£1,924.74
	METHYLPHENIDATE	£1,428.25	£4,237.25	£4,488.90	£2,663.95	£6,642.23	£8,527.19	£7,970.74	£9,051.50	£13,403.84	£15,849.83	£20,422.59	£23,584.07
Cwm Taf Total		£1,683.01	£4,508.57	£5,389.24	£5,233.65	£8,380.97	£10,261.49	£9,394.43	£13,888.82	£18,769.59	£21,109.18	£28,313.04	£34,348.72
Hywel Dda	ATOMOXETINE			£758.10	£3,619.08	£3,269.73	£6,669.20	£9,763.05	£7,440.20	£7,179.74	£9,079.47	£13,738.90	£13,121.46
	DEXAMFETAMINE SULPHATE	£39.51	£437.95	£463.54	£661.39	£679.31	£673.63	£651.51	£650.03	£1,242.62	£1,632.37	£48.72	£1,422.61
	LISDEXAMPHETAMINE DIMESYLATE												£2,636.88
	METHYLPHENIDATE	£1,639.13	£2,462.71	£3,871.46	£5,114.52	£11,545.14	£16,608.42	£14,705.34	£12,094.98	£12,939.24	£18,355.45	£14,966.54	£16,528.24
Hywel Dda Total		£1,678.64	£2,900.66	£5,093.10	£9,394.99	£15,494.18	£23,951.25	£25,119.90	£20,185.21	£21,361.60	£29,067.29	£28,754.16	£33,709.19
Velindre	DEXAMFETAMINE SULPHATE		£6.78	£13.87	£12.64	£45.03	£14.10	£4.79	£4.28		£2.77		£58.48
	METHYLPHENIDATE	-£0.54		£3.26	£0.47		£0.95		£1.39		£15.56	£17.14	
Velindre Total		-£0.54	£6.78	£17.13	£13.11	£45.03	£15.05	£4.79	£5.67		£18.33	£17.14	£58.48
Grand Total		£17,836.76	£23,798.97	£35,706.72	£47,650.96	£62,766.04	£85,199.86	£95,852.88	£110,396.14	£124,561.64	£143,023.28	£141,301.71	£170,673.56

Value				Year													
Trust name	BNF cha	BNF class	Drug Name	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	Grand Total	
ABMU	4	04.04	ATOMOXETINE			3320.445	5340.9857	3719.1687	8222.8901	9312.4817	14802.6808	13925.3196	11123.1361	11828.502	11476.9191	93072.5288	
			DEXAMFETAMINE SULPHATE	172.8489	152.6075	170.9127	280.9346	267.3167	246.4837	448.5644	845.8333	2769.0328	9550.3092	9484.3068	11797.5968	36186.7474	
			LISDEXAMPHETAMINE DIMESYLATE												152.208	152.208	
			METHYLPHENIDATE HYDROCHLORIDE	4328.6073	5105.6258	5251.059	4544.9977	5899.0113	10652.6438	21777.0906	33588.9864	37320.132	35587.2438	23925.8388	33916.4053	221897.6418	
ABMU Total				4501.4562	5258.2333	8742.4167	10166.918	9885.4967	19122.0176	31538.1367	49237.5005	54014.4844	56260.6891	45238.6476	57343.1292	351309.126	
Aneurin Bevan	4	04.04	ATOMOXETINE					114.31	315.93	133.75	171.45	966.11	15.38	138.21	74.95	1930.09	
			DEXAMFETAMINE SULPHATE	62.64	9.04	12.68	5.35	8.99	67.95	180.19	74.43	4.2	6.33	-3.43	131.05	559.42	
			METHYLPHENIDATE HYDROCHLORIDE	1023.58	1563.35	1025.04	1119.89	1575.36	1034.94	506.93	685.77	666.32	575.67	204.77	116	10097.62	
Aneurin Bevan Total				1086.22	1572.39	1037.72	1125.24	1698.66	1418.82	820.87	931.65	1636.63	597.38	339.55	322	12587.13	
BCU	4	04.04	ATOMOXETINE							125.97		136.37		524.75	187.39	974.48	
			DEXAMFETAMINE SULPHATE	30.71	14.31	20.15	1.2	33.89	24.99	59.17	32.2	125.58	375.69	17.53	5098.53	5833.95	
			METHYLPHENIDATE HYDROCHLORIDE	2502.47	154.09	222.14	821.45	348.38	239.16	797.93	627.34	2634.88	2381.64	4348.49	2632.94	17710.91	
BCU Total				2533.18	168.4	242.29	822.65	382.27	264.15	983.07	659.54	2896.83	2757.33	4890.77	7918.86	24519.34	
Cardiff & Vale	4	04.04	ATOMOXETINE				5930.41	3622.1	4700.11	4765.52	5296.83	4407.1	7890.03	8049.03	8244.64	52905.77	
			DEXAMFETAMINE SULPHATE	518.53	510.18	356.56	539.17	344.63	359.47	131.09	56.33	96.85	-43.34	0.49	94.5	2964.46	
			METHYLPHENIDATE HYDROCHLORIDE	5836.26	8873.76	14828.26	14424.82	22912.7	25107.5	23095.07	20134.59	21378.56	25366.39	25698.88	28634.04	236290.83	
Cardiff & Vale Total				6354.79	9383.94	15184.82	20894.4	26879.43	30167.08	27991.68	25487.75	25882.51	33213.08	33748.4	36973.18	292161.06	
Cwm Taf	4	04.04	ATOMOXETINE			586.59	2199.62	1471.64	1361.06	926.82	4362.95	4275.33	3968.6	5849.43	8839.91	33841.95	
			DEXAMFETAMINE SULPHATE	254.76	271.32	313.75	370.08	267.1	373.24	496.87	474.37	1090.42	1290.75	2041.02	1924.74	9168.42	
			METHYLPHENIDATE HYDROCHLORIDE	1428.25	4237.25	4488.9	2663.95	6642.23	8527.19	7970.74	9051.5	13403.84	15849.83	20422.59	23584.07	118270.34	
Cwm Taf Total				1683.01	4508.57	5389.24	5233.65	8380.97	10261.49	9394.43	13888.82	18769.59	21109.18	28313.04	34348.72	161280.71	
Hywel Dda	4	04.04	ATOMOXETINE			758.1	3619.08	3269.73	6669.2	9763.05	7440.2	7179.74	9079.47	13738.9	13121.46	74638.93	
			DEXAMFETAMINE SULPHATE	39.51	437.95	463.54	661.39	679.31	673.63	651.51	650.03	1242.62	1632.37	48.72	1422.61	8603.19	
			LISDEXAMPHETAMINE DIMESYLATE													2636.88	2636.88
			METHYLPHENIDATE HYDROCHLORIDE	1639.13	2462.71	3871.46	5114.52	11545.14	16608.42	14705.34	12094.98	12939.24	18355.45	14966.54	16528.24	130831.17	
Hywel Dda Total				1678.64	2900.66	5093.1	9394.99	15494.18	23951.25	25119.9	20185.21	21361.6	29067.29	28754.16	33709.19	216710.17	
Velindre	4	04.04	DEXAMFETAMINE SULPHATE		6.78	13.87	12.64	45.03	14.1	4.79	4.28		2.77		58.48	162.74	
			METHYLPHENIDATE HYDROCHLORIDE	-0.54		3.26	0.47		0.95		1.39		15.56	17.14			38.23
Velindre Total				-0.54	6.78	17.13	13.11	45.03	15.05	4.79	5.67		18.33	17.14	58.48	200.97	
Grand Total				17836.7562	23798.9733	35706.7167	47650.958	62766.0367	85199.8576	95852.8767	110396.1405	124561.6444	143023.2791	141301.7076	170673.5592	1058768.506	